New inhaled drug shows promise for rare lung disease

NCT ID NCT04816604

Ongoing Disease control Sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at the long-term safety of an inhaled drug called GB002 for people with pulmonary arterial hypertension (PAH), a serious lung condition. It includes 74 patients who already completed a previous GB002 study. Researchers will track side effects and measure how far patients can walk in six minutes to see if the drug helps over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GB002 (seralutinib) inhaled via a dry powder inhaler
What this could lead to: If successful, this could provide a new inhaled treatment option to help control pulmonary arterial hypertension and improve patients' ability to walk.
What could go wrong: This is a small, early-phase extension study with no placebo group, so results may not prove effectiveness. Long-term safety is still unknown, and side effects may emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Show contact details

Locations

AP-HP Hôpital de Bicêtre

Le Kremlin-Bicêtre, 94270, France
Cleveland Clinic Florida

Weston, Florida, 33331, United States
DRK Kliniken Berlin

Berlin, Germany
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Marqués de Valdecilla

Santander, 39008, Spain
Houston Methodist Hospital

Houston, Texas, 77030, United States
INTEGRIS Baptist Medical Center, Inc.

Oklahoma City, Oklahoma, 73112, United States
Imperial College Healthcare NHS Trust - Hammersmith Medicines Research Limited

London, United Kingdom
Klinik für Pneumologie, Klinisches Studienzentrum Medizinische Hochschule

Hanover, 30625, Germany
Klinik und Poliklinik f. Innere Medizin II Universitätsklinikum Regensburg

Regensburg, 93053, Germany
Mayo Clinic

Jacksonville, Florida, 32224, United States
Medical Corporation

Santa Barbara, California, 93105, United States
NYU Langone Health

New York, New York, 10016, United States
New York Presbyterian Hospital - Weill Cornell Medicine

New York, New York, 10065, United States
Norton Pulmonary Specialists

Louisville, Kentucky, 40202, United States
Royal Hobart Hospital

Hobart, Tasmania, 7000, Australia
Royal Papworth Hospital NHS Foundation Trust

Cambridge, CB2 OAY, United Kingdom
St. Vincent's Hospital Melbourne

Fitzroy, Victoria, 3065, Australia
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
Thoraxklinik-Heidelberg gGmbH

Heidelberg, 69126, Germany
Tufts Medical Center

Boston, Massachusetts, 02111, United States
Universitaetsklinikum Giessen und Marburg GmbH - Medizinische Klinik IV und V

Giessen, Germany
University of California, Davis Medical Center

Sacramento, California, 95817, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States
University of Utah Health

Salt Lake City, Utah, 84132, United States
Všeobecná fakultní nemocnice v Praze

Prague, 128 08, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.